SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-382769"
 

Sökning: id:"swepub:oai:DiVA.org:uu-382769" > Emerging Pharmacolo...

Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease : A Review

Chohan, Muhammad O. (författare)
Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA;Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA
Marchio, Serena (författare)
Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA;Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA;Univ Torino, Dept Oncol, Sch Med, Turin, Italy;Ist Ricovero Cura & Carattere Sci, Fdn Piemonte Oncol, Candiolo Canc Inst, Turin, Italy
Morrison, Leslie A. (författare)
Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA
visa fler...
Sidman, Richard L. (författare)
Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA
Cavenee, Webster K. (författare)
Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92103 USA
Dejana, Elisabetta (författare)
Uppsala universitet,Vaskulärbiologi,Fdn Italiana Ric Canc, Inst Mol Oncol Fdn, Milan, Italy;Mario Negri Inst Pharmacol Res, Milan, Italy;Milano Univ, Sch Sci, Dept Biosci, Milan, Italy;Milano Univ, Sch Med, Dept Oncol, Milan, Italy
Yonas, Howard (författare)
Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA
Pasqualini, Renata (författare)
Univ Hosp, Rutgers Canc Inst New Jersey, 205 S Orange Ave, Newark, NJ 07103 USA;Rutgers New Jersey Med Sch, Dept Radiat Oncol, Div Canc Biol, Newark, NJ USA
Arap, Wadih (författare)
Univ Hosp, Rutgers Canc Inst New Jersey, 205 S Orange Ave, Newark, NJ 07103 USA;Rutgers New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ USA
visa färre...
 (creator_code:org_t)
AMER MEDICAL ASSOC, 2019
2019
Engelska.
Ingår i: JAMA Neurology. - : AMER MEDICAL ASSOC. - 2168-6149 .- 2168-6157. ; 76:4, s. 492-500
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • IMPORTANCE: Cerebral cavernous malformations (CCMs) are vascular lesions of the brain that may lead to hemorrhage, seizures, and neurologic deficits. Most are linked to loss-of-function mutations in 1 of 3 genes, namely CCM1 (originally called KRIT1), CCM2 (MGC4607), or CCM3 (PDCD10), that can either occur as sporadic events or are inherited in an autosomal dominant pattern with incomplete penetrance. Familial forms originate from germline mutations, often have multiple intracranial lesions that grow in size and number over time, and cause an earlier and more severe presentation. Despite active preclinical research on a few pharmacologic agents, clinical translation has been slow. Open surgery and, in some cases, stereotactic radiosurgery remain the only effective treatments, but these options are limited by lesion accessibility and are associated with nonnegligible rates of morbidity and mortality.OBSERVATIONS: We discuss the limits of CCM management and introduce findings from in vitro and in vivo studies that provide insight into CCM pathogenesis and indicate molecular mechanisms as potential therapeutic targets. These studies report dysregulated cellular pathways shared between CCM, cardiovascular diseases, and cancer. They also suggest the potential effectiveness of proper drug repurposing in association with, or as an alternative to, targeted interventions.CONCLUSIONS AND RELEVANCE: We propose methods to exploit specific molecular pathways to design patient-tailored therapeutic approaches in CCM, with the aim to alter its natural progression. In this scenario, the lack of effective pharmacologic options remains a critical barrier that poses an unfulfilled and urgent medical need.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy